TY  - JOUR
AU  - Lorio, Sara
AU  - Sambataro, Fabio
AU  - Bertolino, Alessandro
AU  - Draganski, Bogdan
AU  - Dukart, Jürgen
TI  - The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson’s Disease
JO  - Frontiers in aging neuroscience
VL  - 11
SN  - 1663-4365
CY  - Lausanne
PB  - Frontiers Research Foundation
M1  - FZJ-2019-01932
SP  - 57
PY  - 2019
N1  - FUNDINGData   used   in   the   preparation   of   this   article   were   obtainedfrom  the  PPMI  database  (www.ppmi-info.org/data).  For  up-to-date   information   on   the   study,   visit   www.ppmi-info.org.PPMI   –   a   public-private   partnership   –   is   funded   by   theMichael   J.   Fox   Foundation   for   Parkinson’s   Research   andfunding partners, including Abbvie, Avid Radiopharmaceuticals,Biogen  Idec,  Briston-Myers  Squibb,  Covance,  GE  Healthcare,Genentech,   GlaxoSmithKline,   Lilly,   Lundbeck,   Merck,   MesoScale   Discovery,   Pfizer,   Piramal,   Roche,   and   UCB.   SL   wassupported   by   the   National   Institute   for   Health   ResearchBiomedical  Research  Centre  at  Great  Ormond  Street  Hospitalfor Children NHS Foundation Trust, The Henry Smith Charity,and  Action  Medical  Research  (GN2214).  BD  was  supportedby  the  Swiss  National  Science  Foundation  (project  grant  no.32003B_159780   and   SPUM   33CM30_140332/1),   FoundationParkinson  Switzerland,  Foundation  Synapsis.  LREN  is  gratefulto  the  Roger  de  Spoelberch  and  the  Partridge  Foundations  fortheir generous support
AB  - There is an increasing interest in identifying non-invasive biomarkers of disease severityand  prognosis  in  idiopathic  Parkinson’s  disease  (PD).  Dopamine-transporter  SPECT(DAT-SPECT), diffusion tensor imaging (DTI), and structural magnetic resonance imaging(sMRI) provide unique information about the brain’s neurotransmitter and microstructuralproperties.  In  this  study,  we  evaluate  the  relative  and  combined  capability  of  theseimaging modalities to predict symptom severity and clinical progression inde novoPDpatients. To this end, we used MRI, SPECT, and clinical data ofde novodrug-naïvePD  patients  (n=  205,  mean  age  61±10)  and  age-,  sex-matched  healthy  controls(n= 105, mean age 58±12) acquired at baseline. Moreover, we employed clinical dataacquired at 1 year follow-up for PD patients with or withoutL-Dopa treatment in orderto  predict  the  progression  symptoms  severity.  Voxel-based  group  comparisons  andcovariance analyses were applied to characterize baseline disease-related alterations forDAT-SPECT, DTI, and sMRI. Cortical and subcortical alterations inde novoPD patientswere found in all evaluated imaging modalities, in line with previously reported midbrain-striato-cortical network alterations. The combination of these imaging alterations wasreliably  linked  to  clinical  severity  and  disease  progression  at  1  year  follow-up  in  thispatient  population,  providing  evidence  for  the  potential  use  of  these  modalities  asimaging  biomarkers  for  disease  severity  and  prognosis  that  can  be  integrated  intoclinical trials.
LB  - PUB:(DE-HGF)16
C6  - pmid:30930768
UR  - <Go to ISI:>//WOS:000461685400001
DO  - DOI:10.3389/fnagi.2019.00057
UR  - https://juser.fz-juelich.de/record/861467
ER  -